The funding will be used to advance a study of Cognito’s flagship neuromodulation device. The latest funding round brings the company’s total raised to $93 million, according to a March 22 Cognito news release.
FoundersX Ventures led the financing round.
“This funding will accelerate development of Cognito’s home-based wearable device which has the potential to be a novel, safe, disease-modifying therapeutic approach to treat neurodegenerative diseases, starting with Alzheimer’s,” Cognito CEO Brent Vaughan said in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
